StockCIK 872589

REGENERON PHARMACEUTICALS, INC. (REGN): Insider Trades and Fund Holdings

In the past 12 months, REGENERON PHARMACEUTICALS, INC. insiders reported 0 open-market purchases worth $0 and 4 sales worth $5.55M; 4 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$5.55MSold by insiders, 12 months

2Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 15, 2026.

Recent REGN insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 15	Oct 14	Andrew J. MurphyCo-Chief Scientific Officer	Co-Chief Scientific Officer	▼ SELL10b5-1	4,147	772.70	$3.20M	−7.4%	Form 4 ↗
Sep 3	Sep 2	Marion McCourtEVP	EVP	▼ SELL10b5-1	1,215	850.00	$1.03M	−8.5%	Form 4 ↗
Sep 3	Sep 3	Marion McCourtEVP	EVP	▼ SELL10b5-1	1,131	857.39	$970K	−8.6%	Form 4 ↗
Sep 3	Sep 2	Kathryn GuariniDirector	Director	▼ SELL10b5-1	400	850.00	$340K	−40%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Bought	Sells	Sold	Latest
Andrew J. Murphy	Co-Chief Scientific Officer	$0	1	$3.20M	Oct 15, 2026
Marion McCourt	EVP	$0	2	$2.00M	Sep 3, 2026
Kathryn Guarini	Director	$0	1	$340K	Sep 3, 2026

Tracked funds that report REGN

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	148,222	$92.4M	0.13%	▲ +121.9%
Bridgewater Associates	Q2 2026	51,333	$32.0M	0.13%	▲ +125.9%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →